Tag:
M&A;
Latest Headlines
Latest Headlines
Pfizer likely to pull the plug on Allergan deal: Reuters
Pfizer may be able to find a way to salvage its $160 billion merger with Allergan, even after the U.S. Treasury Department's latest efforts to curb tax inversions. But word has it, it doesn't want to.
What would Pfizer do without Allergan--and Allergan without Pfizer?
The U.S. Treasury's new rules might end Pfizer's quest for a tax inversion and put Allergan back on its previous course as an independent company. The key word is "might." But if the $160 billion merger does collapse, both companies will need new maps to growth.
Warburg-backed Sterigenics buys Nelson Labs to create largest sterilization, testing firm
Contract sterilization player Sterigenics, which was acquired last year in a deal reportedly valued at $2 billion by private equity firms Warburg Pincus and GTCR, has bought Nelson Laboratories. The deal wraps the largest U.S. sterility testing services for medical devices, pharmaceuticals and tissues into the Warburg portfolio company--making it the largest provider globally of sterilization services and testing, according to the company.
UPDATED: It's a Pfizer vs. Obama matchup as Treasury suits up to fight Allergan merger
President Barack Obama has made no secret of his contempt for Pfizer's plans to merge with Allergan to move its headquarters to tax-friendly Ireland. Pfizer CEO Ian Read has made no secret of his determination to close that $160 billion deal, political backlash or no.
With deal scouts knocking, Medivation hires JPMorgan to man the door
Potential buyers are circling Medivation, the cancer-focused drugmaker that recently brought Xtandi to market. But the San Francisco-based company isn't interested, Reuters says--and it has hired investment bankers at JPMorgan Chase to help fend off a deal.
FTC digs deeper into Pfizer's proposed combo with Allergan
Not so fast, Pfizer and Allergan. Regulators are looking for more information on their agreed-upon megamerger before allowing it to proceed.
WPP Group buys CMI healthcare and pharma media agency
Adding to its healthcare heft, WPP Group bought CMI, a healthcare media agency that counts 10 of the largest 20 pharma advertisers among its clients.
Affymetrix spurns bid by former execs in favor of $1.3B offer from Thermo Fisher
Affymetrix, a maker of advanced genetic analysis technology, has rejected an unsolicited bid by former executives in favor of the $1.3 billion offer it received from Thermo Fisher Scientific earlier this year.
Bristol-Myers bags biotech upstart Padlock in $600M autoimmune deal
Bristol-Myers Squibb has struck a $600 million deal to buy out the biotech startup Padlock Therapeutics and its autoimmune R&D; platform.
Precision for Medicine broadens cancer trial offering with ACT Oncology buy
Precision for Medicine has signed a deal to acquire ACT Oncology--a leading CRO in the field of cancer studies--as together the new company looks to become a leading light in the personalized cancer clinical trial space.
